2ad90ba0-8038-4bad-afa3-d176f63b42f0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.580
- MYC_TARGETS_V1+0.540
- ALLOGRAFT_REJECTION+0.510
- INTERFERON_ALPHA_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.430
- MTORC1_SIGNALING+0.420
- MYC_TARGETS_V2+0.410
- DNA_REPAIR+0.400
- IL6_JAK_STAT3_SIGNALING+0.380
- FATTY_ACID_METABOLISM+0.370
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.650
- APICAL_SURFACE-0.500
- MITOTIC_SPINDLE-0.410
- WNT_BETA_CATENIN_SIGNALING-0.370
- UV_RESPONSE_DN-0.340
- APICAL_JUNCTION-0.330
- MYOGENESIS-0.330
- ANGIOGENESIS-0.260
- TGF_BETA_SIGNALING-0.260
- KRAS_SIGNALING_DN-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.917 |
| 2 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.895 |
| 3 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.887 |
| 4 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.883 |
| 5 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.876 |
| 6 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.876 |
| 7 | 57901dc3-9b2f-4271-8dd9-8fc0121d6971 | — | — | 0.875 |
| 8 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.862 |
| 9 | ERR2208906 | — | — | 0.861 |
| 10 | SRR9879275 | — | cohortA1 | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.580 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.370 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |